Literature DB >> 18824881

Synchronous and metachronous extrapancreatic malignant neoplasms in patients with intraductal papillary-mucinous neoplasm of the pancreas.

Masaharu Ishida1, Shinichi Egawa, Kei Kawaguchi, Takeshi Aoki, Naoaki Sakata, Yukio Mikami, Fuyuhiko Motoi, Tadayoshi Abe, Shoji Fukuyama, Yu Katayose, Makoto Sunamura, Michiaki Unno, Takuya Moriya, Akira Horii, Toru Furukawa.   

Abstract

BACKGROUND/AIMS: Patients with intraductal papillary-mucinous neoplasm (IPMN) of the pancreas are likely to have a better prognosis than those with conventional pancreatic ductal adenocarcinoma. Recently there have been some reports on extrapancreatic malignant neoplasms (EPM) occurring in patients with IPMN. The purpose of this study was to discover the characteristic features of IPMN with EPM compared with IPMN without EPM.
METHODS: 61 patients with IPMN who underwent surgery at Tohoku University Hospital between 1988 and 2006 were retrospectively analyzed.
RESULTS: The 61 patients with IPMN in this study comprised 25 with intraductal papillary-mucinous adenomas (IPMA) and 36 with intraductal papillary-mucinous carcinomas (IPMC) including 6 with invasive carcinomas. Synchronous and metachronous EPM were observed in 15 out of the 61 patients (24.6%). Three of these patients, including 2 with IPMA and 1 with invasive carcinoma associated with IPMC, died of the EPM. None of the features, including sex, age, smoking, family history, macroscopic types (main duct type or branch duct type), histological types (gastric, intestinal, pancreatobiliary or oncocytic), and aberrant expression of molecules including CDKN2A, TP53, SMAD4 and DUSP6, except for the histological diagnoses were associated with the occurrence of EPM, i.e., the EPM occurred more often in patients with IPMA (10 out of 25) than in those with IPMC (5 out of 36) in our series (p = 0.0199 by the chi(2) test, p = 0.0330 by Fisher's exact probability test, p = 0.0422 by Yates' correction).
CONCLUSION: Patients with IPMA were more likely to have EPM than those with IPMC. Patients with IPMA are usually expected to have a fair prognosis but EPM could be fatal in some of them, so it must be noted during follow-up. Copyright 2008 S. Karger AG, Basel and IAP.

Entities:  

Mesh:

Year:  2008        PMID: 18824881     DOI: 10.1159/000159844

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  16 in total

1.  Predictive factors associated with malignancy of intraductal papillary mucinous pancreatic neoplasms.

Authors:  Jin Hee Lee; Kyu Taek Lee; Jongwook Park; Sun Youn Bae; Kwang Hyuck Lee; Jong Kyun Lee; Kee-Taek Jang; Jin Seok Heo; Seong Ho Choi; Dong Wook Choi; Jong Chul Rhee
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

Review 2.  IPMN: surgical treatment.

Authors:  Reto M Käppeli; Sascha A Müller; Bianka Hummel; Christina Kruse; Philip Müller; Jürgen Fornaro; Alexander Wilhelm; Marcel Zadnikar; Bruno M Schmied; Ignazio Tarantino
Journal:  Langenbecks Arch Surg       Date:  2013-09-03       Impact factor: 3.445

3.  Pancreatobiliary and pancreatoduodenal fistulae in intraductal papillary mucinous neoplasm of the pancreas: report of a case.

Authors:  Jan Jin Bong; Jayson Wang; Duncan R Spalding
Journal:  Surg Today       Date:  2011-01-26       Impact factor: 2.549

4.  Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting.

Authors:  Volkan Adsay; Mari Mino-Kenudson; Toru Furukawa; Olca Basturk; Giuseppe Zamboni; Giovanni Marchegiani; Claudio Bassi; Roberto Salvia; Giuseppe Malleo; Salvatore Paiella; Christopher L Wolfgang; Hanno Matthaei; G Johan Offerhaus; Mustapha Adham; Marco J Bruno; Michelle D Reid; Alyssa Krasinskas; Günter Klöppel; Nobuyuki Ohike; Takuma Tajiri; Kee-Taek Jang; Juan Carlos Roa; Peter Allen; Carlos Fernández-del Castillo; Jin-Young Jang; David S Klimstra; Ralph H Hruban
Journal:  Ann Surg       Date:  2016-01       Impact factor: 12.969

5.  Metachronous double cancer after curative resection for pancreatic adenocarcinoma: report of four cases.

Authors:  Yoshito Ikematsu; Hiroaki Tamura; Tadataka Hayashi; Yuji Tokunaga; Yuki Misawa; Hiroki Mori; Shinichi Hasegawa; Taketoshi Okawada; Takachika Ozawa; Shigeru Momiki; Yoshiro Nishiwaki
Journal:  Clin J Gastroenterol       Date:  2011-12-28

6.  Prognosis of cancer with branch duct type IPMN of the pancreas.

Authors:  Nobuhito Ikeuchi; Takao Itoi; Atsushi Sofuni; Fumihide Itokawa; Takayoshi Tsuchiya; Toshio Kurihara; Kentaro Ishii; Shujiro Tsuji; Junko Umeda; Fuminori Moriyasu; Akihiko Tsuchida; Kazuhiko Kasuya
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

Review 7.  Increased risk of second malignancy in pancreatic intraductal papillary mucinous tumors: Review of the literature.

Authors:  Gian Luca Baiocchi; Sarah Molfino; Barbara Frittoli; Graziella Pigozzi; Federico Gheza; Giacomo Gaverini; Antonio Tarasconi; Chiara Ricci; Francesco Bertagna; Luigi Grazioli; Guido A M Tiberio; Nazario Portolani
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

Review 8.  Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter?

Authors:  Deepika Nehra; Vicente Morales Oyarvide; Mari Mino-Kenudson; Sarah P Thayer; Cristina R Ferrone; Jennifer A Wargo; Alona Muzikansky; Dianne Finkelstein; Andrew L Warshaw; Carlos Fernández-del Castillo
Journal:  Pancreatology       Date:  2012-06-15       Impact factor: 3.996

9.  Concomitant intraductal papillary mucinous neoplasm and neuroendocrine tumor of the pancreas.

Authors:  Mitsuaki Ishida; Hisanori Shiomi; Shigeyuki Naka; Tohru Tani; Hidetoshi Okabe
Journal:  Oncol Lett       Date:  2012-10-03       Impact factor: 2.967

Review 10.  Malignant potential of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Yoshiyuki Nakajima; Takatsugu Yamada; Masayuki Sho
Journal:  Surg Today       Date:  2010-08-26       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.